Rivory L P, Robert J
University of Bordeaux II, France.
J Chromatogr B Biomed Appl. 1994 Nov 4;661(1):133-41. doi: 10.1016/0378-4347(94)00340-8.
Irinotecan, also known as CPT-11 (I), is a potent semi-synthetic derivative of 20(S)-camptothecin (CPT). Like all known active derivatives of CPT, the lactone forms of I and its active metabolite SN-38 (II) are reversibly hydrolysed to inactive carboxylate forms. We describe a sensitive and selective HPLC method using the ion-pairing reagent tetrabutylammonium phosphate (TBAP) which allows the simultaneous determination of the carboxylate and lactone forms of I and II in human plasma samples following the precipitation of plasma proteins with an ice-cold mixture of acetonitrile and methanol. The mobile phase was 0.075 M ammonium acetate buffer (pH 6.4)-acetonitrile (78:22, v/v) containing 5 mM TBAP. Separation of the compounds was performed on a radially-compressed C18 column. The limits of quantitation in human plasma were 2 and 10 ng/ml for the two forms of II and I, respectively. In addition, we propose the use of CPT lactone both as an internal standard and as a "watchdog" for sample status. Under unsuitable storage conditions, CPT elutes increasingly in its carboxylate form thereby alerting the operator of possibly erroneous determinations of the concentrations of both forms of I and II. The retention times of the peaks of interest are well separated from the solvent front. This enables the detection of early eluting metabolites. The method was successfully used for monitoring of the two forms of I and II in patients treated with I.
伊立替康,也称为CPT - 11(I),是20(S)-喜树碱(CPT)的一种强效半合成衍生物。与所有已知的CPT活性衍生物一样,I及其活性代谢物SN - 38(II)的内酯形式会可逆地水解为无活性的羧酸盐形式。我们描述了一种灵敏且选择性高的高效液相色谱法,该方法使用离子对试剂磷酸四丁铵(TBAP),通过用冰冷的乙腈和甲醇混合物沉淀血浆蛋白后,可同时测定人血浆样品中I和II的羧酸盐形式和内酯形式。流动相为含有5 mM TBAP的0.075 M醋酸铵缓冲液(pH 6.4)-乙腈(78:22,v/v)。化合物在径向压缩的C18柱上进行分离。人血浆中两种形式的II和I的定量限分别为2和10 ng/ml。此外,我们建议将CPT内酯既用作内标,又用作样品状态的“监测指标”。在不合适的储存条件下,CPT以其羧酸盐形式洗脱的比例会越来越高,从而提醒操作人员I和II两种形式的浓度测定可能有误。感兴趣峰的保留时间与溶剂前沿分离良好。这使得能够检测出早期洗脱的代谢物。该方法已成功用于监测接受I治疗患者体内I和II的两种形式。